| 000 | 01451 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250513113949.0 | ||
| 264 | 0 | _c19970619 | |
| 008 | 199706s 0 0 eng d | ||
| 022 | _a0271-0749 | ||
| 024 | 7 |
_a10.1097/00004714-199704001-00004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDelbressine, L P | |
| 245 | 0 | 0 |
_aThe clinical relevance of preclinical data: mirtazapine, a model compound. _h[electronic resource] |
| 260 |
_bJournal of clinical psychopharmacology _cApr 1997 |
||
| 300 |
_a29S-33S p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntidepressive Agents, Tricyclic _xmetabolism |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 |
_aBrain _xmetabolism |
| 650 | 0 | 4 | _aCytochrome P-450 Enzyme Inhibitors |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xmetabolism |
| 650 | 0 | 4 |
_aDepressive Disorder _xdrug therapy |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 | _aMetabolic Clearance Rate |
| 650 | 0 | 4 |
_aMianserin _xanalogs & derivatives |
| 650 | 0 | 4 | _aMirtazapine |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aProtein Binding |
| 700 | 1 | _aVos, R M | |
| 773 | 0 |
_tJournal of clinical psychopharmacology _gvol. 17 Suppl 1 _gp. 29S-33S |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00004714-199704001-00004 _zAvailable from publisher's website |
| 999 |
_c9074104 _d9074104 |
||